[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @ByMadeleineA Madeleine Armstrong Madeleine Armstrong posts on X about $azn, $pfe, $arvn, $dskny the most. They currently have XXXXX followers and XXX posts still getting attention that total XXXXXX engagements in the last XX hours. ### Engagements: XXXXXX [#](/creator/twitter::14673628/interactions)  - X Week XXXXXX +134% - X Month XXXXXX +254% - X Months XXXXXXX -XX% - X Year XXXXXXX -XX% ### Mentions: XX [#](/creator/twitter::14673628/posts_active)  - X Week XX -XX% - X Month XX +29% - X Months XXX -XX% - X Year XXX +15% ### Followers: XXXXX [#](/creator/twitter::14673628/followers)  - X Week XXXXX +0.16% - X Month XXXXX +0.41% - X Months XXXXX +2.40% - X Year XXXXX +4.60% ### CreatorRank: XXXXXXX [#](/creator/twitter::14673628/influencer_rank)  ### Social Influence [#](/creator/twitter::14673628/influence) --- **Social category influence** [stocks](/list/stocks) XXXXX% [currencies](/list/currencies) #1288 **Social topic influence** [$azn](/topic/$azn) #8, [$pfe](/topic/$pfe) #29, [$arvn](/topic/$arvn) #1, [$dskny](/topic/$dskny) #1, [$dsnky](/topic/$dsnky) #1, [$gild](/topic/$gild) #2, [$jnj](/topic/$jnj) #2, [$mrk](/topic/$mrk) #28, [$lly](/topic/$lly) #9, [$iphas](/topic/$iphas) XXXX% **Top accounts mentioned or mentioned by** [@apexonco](/creator/undefined) [@jacobplieth](/creator/undefined) [@financebully](/creator/undefined) [@adar170](/creator/undefined) [@jacobplieths](/creator/undefined) [@evaluatevantage](/creator/undefined) [@biotwit1](/creator/undefined) [@conkers3](/creator/undefined) [@houndcl](/creator/undefined) [@ksaraholland](/creator/undefined) [@biotechch](/creator/undefined) [@anthonystaj](/creator/undefined) [@biotech2050](/creator/undefined) [@schaeffers](/creator/undefined) [@pearlf](/creator/undefined) [@onco_park](/creator/undefined) [@jacksha90859576](/creator/undefined) [@evaluatepharma](/creator/undefined) [@ablt315i](/creator/undefined) **Top assets mentioned** [AstraZeneca PLC (AZN)](/topic/$azn) [Pfizer, Inc. (PFE)](/topic/$pfe) [Arvinas, Inc (ARVN)](/topic/$arvn) [Gilead Sciences, Inc. (GILD)](/topic/$gild) [Johnson & Johnson (JNJ)](/topic/$jnj) [Merck & Co., Inc. (MRK)](/topic/$mrk) [Eli Lilly and Company (LLY)](/topic/$lly) [Sanofi (SNY)](/topic/sanofi) [Synthetify (SNY)](/topic/$sny) [Novartis AG (NVS)](/topic/$nvs) ### Top Social Posts [#](/creator/twitter::14673628/posts) --- Top posts by engagements in the last XX hours "Sounds like more bad news for $IPHA's NK engagers. Here's my previous take on $SNY handing back other NK projects" [X Link](https://x.com/ByMadeleineA/status/1968236399372677535) [@ByMadeleineA](/creator/x/ByMadeleineA) 2025-09-17T08:51Z 8078 followers, 2196 engagements "Compare the wording on OS from $AZN & $DSKNY on Tropion-Breast02 vs $GILD on Ascent-03. Datroway "stat sig & clinically meaningful" on both PFS & OS but only "no OS detriment" for Trodelvy" [X Link](https://x.com/ByMadeleineA/status/1975114941582717427) [@ByMadeleineA](/creator/x/ByMadeleineA) 2025-10-06T08:24Z 8078 followers, 9293 engagements "$PFE jumps straight from phase X to phase X with its EZH2 inhibitor mevrometostat. What could possibly go wrong Via @ApexOnco $IPN.PA $DSNKY $NVS" [X Link](https://x.com/ByMadeleineA/status/1825509871296364953) [@ByMadeleineA](/creator/x/ByMadeleineA) 2024-08-19T12:27Z 8059 followers, 5564 engagements "WTF Arvinas and Pfizer plan to jointly select third party for the out-licensing and commercialization of vepdegestrant $ARVN $PFE" [X Link](https://x.com/ByMadeleineA/status/1968413264842199526) [@ByMadeleineA](/creator/x/ByMadeleineA) 2025-09-17T20:34Z 8063 followers, 8775 engagements "Who will buy vepdeg $ARVN $PFE" [X Link](https://x.com/ByMadeleineA/status/1968646368836079811) [@ByMadeleineA](/creator/x/ByMadeleineA) 2025-09-18T12:00Z 8063 followers, 2637 engagements "Enhertus perioperative Destiny beckons but watch out for ILD. The @ApexOnco take on Destiny-Breast05 & Destiny-Breast11 data at #ESMO25 $AZN $DSKNY" [X Link](https://x.com/ByMadeleineA/status/1979604977753460771) [@ByMadeleineA](/creator/x/ByMadeleineA) 2025-10-18T17:46Z 8079 followers, 2892 engagements "Cross-trial comparison of Datroway vs Trodelvy in first-line TNBC at #ESMO25. $AZN & $DSNKY have the edge over $GILD (OS data immature with Trodelvy)" [X Link](https://x.com/ByMadeleineA/status/1979802489672319468) [@ByMadeleineA](/creator/x/ByMadeleineA) 2025-10-19T06:51Z 8079 followers, 4438 engagements "$JNJ claims a Tecvayli/Darzalex combo win with a PFS & OS benefit in Majestec-3" [X Link](https://x.com/ByMadeleineA/status/1978793659735675256) [@ByMadeleineA](/creator/x/ByMadeleineA) 2025-10-16T12:02Z 8070 followers, 2567 engagements "And another trial failure sneaked into Q2 earnings this time for $GSK's anti-TIM3 MAb cobolimab" [X Link](https://x.com/ByMadeleineA/status/1950483945394516435) [@ByMadeleineA](/creator/x/ByMadeleineA) 2025-07-30T09:09Z 8076 followers, 5157 engagements "$AZN gives the PDUFA date for Enhertu + Perjeta in 1st-line HER2+ve as "Q1 2026" but $DSKNY is more specific: XX Jan (use based on Destiny-Breast09)" [X Link](https://x.com/ByMadeleineA/status/1970769069206052892) [@ByMadeleineA](/creator/x/ByMadeleineA) 2025-09-24T08:35Z 8076 followers, 2940 engagements "We were right about Tropion-Breast02 $AZN #ESMO25" [X Link](https://x.com/ByMadeleineA/status/1977658659653226681) [@ByMadeleineA](/creator/x/ByMadeleineA) 2025-10-13T08:52Z 8079 followers, 5183 engagements "$MRK has just toplined overall survival success in all comers in Keynote-B96 in platinum-resistant ovarian cancer. Previously said it hit on PFS & OS in PD-L1 expressers and data are coming at but it sounds like the new OS analysis won't be #ESMO25" [X Link](https://x.com/ByMadeleineA/status/1978777845104050612) [@ByMadeleineA](/creator/x/ByMadeleineA) 2025-10-16T10:59Z 8078 followers, 1098 engagements "$RHHY is out with oral SERD data ahead of its #ESMO25 presentation. The ITT result looks clearly driven by ESR1m pts; the question now is whether Roche has done enough to get a broad label $LLY $ARVN $PFE" [X Link](https://x.com/ByMadeleineA/status/1979417010497872017) [@ByMadeleineA](/creator/x/ByMadeleineA) 2025-10-18T05:19Z 8079 followers, 4674 engagements "Well these are the most promising signs I think we've seen in non-ESR1m pts with a SERD. And $RHHBY has been clever by enrolling XX% of pts in Evera with ESR1m. Now over to the FDA #ESMO25 $LLY $PFE $ARVN" [X Link](https://x.com/ByMadeleineA/status/1979466325064880363) [@ByMadeleineA](/creator/x/ByMadeleineA) 2025-10-18T08:35Z 8078 followers, 1697 engagements "Padcev plus Keytruda sets the perioperative bladder cancer bar at #ESMO25 $PFE $ALPMF $MRK" [X Link](https://x.com/ByMadeleineA/status/1979599881590153668) [@ByMadeleineA](/creator/x/ByMadeleineA) 2025-10-18T17:26Z 8078 followers, 1714 engagements "The #ESMO25 discussant Dr Ana Garrido-Castro weighs in on how to choose between Trodelvy & Datroway" [X Link](https://x.com/ByMadeleineA/status/1979819710893138065) [@ByMadeleineA](/creator/x/ByMadeleineA) 2025-10-19T07:59Z 8079 followers, XXX engagements "Missed this at the time of the presentation as footnote is so small: X gr3 pneumonitis then death in Tropion-Breast02 was deemed related to disease $AZN $DSNKY #ESMO25" [X Link](https://x.com/ByMadeleineA/status/1979846122308026423) [@ByMadeleineA](/creator/x/ByMadeleineA) 2025-10-19T09:44Z 8078 followers, 3314 engagements "$JNJ sees early promise with Rybrevant in relapsed head & neck cancer and is planning a phase X first-line trial. I spoke to the company ahead of #ESMO25 for @ApexOnco" [X Link](https://x.com/ByMadeleineA/status/1979918916836012310) [@ByMadeleineA](/creator/x/ByMadeleineA) 2025-10-19T14:33Z 8079 followers, 5894 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@ByMadeleineA Madeleine Armstrong
Madeleine Armstrong posts on X about $azn, $pfe, $arvn, $dskny the most. They currently have XXXXX followers and XXX posts still getting attention that total XXXXXX engagements in the last XX hours.
Engagements: XXXXXX #
- X Week XXXXXX +134%
- X Month XXXXXX +254%
- X Months XXXXXXX -XX%
- X Year XXXXXXX -XX%
Mentions: XX #
- X Week XX -XX%
- X Month XX +29%
- X Months XXX -XX%
- X Year XXX +15%
Followers: XXXXX #
- X Week XXXXX +0.16%
- X Month XXXXX +0.41%
- X Months XXXXX +2.40%
- X Year XXXXX +4.60%
CreatorRank: XXXXXXX #
Social Influence #
Social category influence stocks XXXXX% currencies #1288
Social topic influence $azn #8, $pfe #29, $arvn #1, $dskny #1, $dsnky #1, $gild #2, $jnj #2, $mrk #28, $lly #9, $iphas XXXX%
Top accounts mentioned or mentioned by @apexonco @jacobplieth @financebully @adar170 @jacobplieths @evaluatevantage @biotwit1 @conkers3 @houndcl @ksaraholland @biotechch @anthonystaj @biotech2050 @schaeffers @pearlf @onco_park @jacksha90859576 @evaluatepharma @ablt315i
Top assets mentioned AstraZeneca PLC (AZN) Pfizer, Inc. (PFE) Arvinas, Inc (ARVN) Gilead Sciences, Inc. (GILD) Johnson & Johnson (JNJ) Merck & Co., Inc. (MRK) Eli Lilly and Company (LLY) Sanofi (SNY) Synthetify (SNY) Novartis AG (NVS)
Top Social Posts #
Top posts by engagements in the last XX hours
"Sounds like more bad news for $IPHA's NK engagers. Here's my previous take on $SNY handing back other NK projects"
X Link @ByMadeleineA 2025-09-17T08:51Z 8078 followers, 2196 engagements
"Compare the wording on OS from $AZN & $DSKNY on Tropion-Breast02 vs $GILD on Ascent-03. Datroway "stat sig & clinically meaningful" on both PFS & OS but only "no OS detriment" for Trodelvy"
X Link @ByMadeleineA 2025-10-06T08:24Z 8078 followers, 9293 engagements
"$PFE jumps straight from phase X to phase X with its EZH2 inhibitor mevrometostat. What could possibly go wrong Via @ApexOnco $IPN.PA $DSNKY $NVS"
X Link @ByMadeleineA 2024-08-19T12:27Z 8059 followers, 5564 engagements
"WTF Arvinas and Pfizer plan to jointly select third party for the out-licensing and commercialization of vepdegestrant $ARVN $PFE"
X Link @ByMadeleineA 2025-09-17T20:34Z 8063 followers, 8775 engagements
"Who will buy vepdeg $ARVN $PFE"
X Link @ByMadeleineA 2025-09-18T12:00Z 8063 followers, 2637 engagements
"Enhertus perioperative Destiny beckons but watch out for ILD. The @ApexOnco take on Destiny-Breast05 & Destiny-Breast11 data at #ESMO25 $AZN $DSKNY"
X Link @ByMadeleineA 2025-10-18T17:46Z 8079 followers, 2892 engagements
"Cross-trial comparison of Datroway vs Trodelvy in first-line TNBC at #ESMO25. $AZN & $DSNKY have the edge over $GILD (OS data immature with Trodelvy)"
X Link @ByMadeleineA 2025-10-19T06:51Z 8079 followers, 4438 engagements
"$JNJ claims a Tecvayli/Darzalex combo win with a PFS & OS benefit in Majestec-3"
X Link @ByMadeleineA 2025-10-16T12:02Z 8070 followers, 2567 engagements
"And another trial failure sneaked into Q2 earnings this time for $GSK's anti-TIM3 MAb cobolimab"
X Link @ByMadeleineA 2025-07-30T09:09Z 8076 followers, 5157 engagements
"$AZN gives the PDUFA date for Enhertu + Perjeta in 1st-line HER2+ve as "Q1 2026" but $DSKNY is more specific: XX Jan (use based on Destiny-Breast09)"
X Link @ByMadeleineA 2025-09-24T08:35Z 8076 followers, 2940 engagements
"We were right about Tropion-Breast02 $AZN #ESMO25"
X Link @ByMadeleineA 2025-10-13T08:52Z 8079 followers, 5183 engagements
"$MRK has just toplined overall survival success in all comers in Keynote-B96 in platinum-resistant ovarian cancer. Previously said it hit on PFS & OS in PD-L1 expressers and data are coming at but it sounds like the new OS analysis won't be #ESMO25"
X Link @ByMadeleineA 2025-10-16T10:59Z 8078 followers, 1098 engagements
"$RHHY is out with oral SERD data ahead of its #ESMO25 presentation. The ITT result looks clearly driven by ESR1m pts; the question now is whether Roche has done enough to get a broad label $LLY $ARVN $PFE"
X Link @ByMadeleineA 2025-10-18T05:19Z 8079 followers, 4674 engagements
"Well these are the most promising signs I think we've seen in non-ESR1m pts with a SERD. And $RHHBY has been clever by enrolling XX% of pts in Evera with ESR1m. Now over to the FDA #ESMO25 $LLY $PFE $ARVN"
X Link @ByMadeleineA 2025-10-18T08:35Z 8078 followers, 1697 engagements
"Padcev plus Keytruda sets the perioperative bladder cancer bar at #ESMO25 $PFE $ALPMF $MRK"
X Link @ByMadeleineA 2025-10-18T17:26Z 8078 followers, 1714 engagements
"The #ESMO25 discussant Dr Ana Garrido-Castro weighs in on how to choose between Trodelvy & Datroway"
X Link @ByMadeleineA 2025-10-19T07:59Z 8079 followers, XXX engagements
"Missed this at the time of the presentation as footnote is so small: X gr3 pneumonitis then death in Tropion-Breast02 was deemed related to disease $AZN $DSNKY #ESMO25"
X Link @ByMadeleineA 2025-10-19T09:44Z 8078 followers, 3314 engagements
"$JNJ sees early promise with Rybrevant in relapsed head & neck cancer and is planning a phase X first-line trial. I spoke to the company ahead of #ESMO25 for @ApexOnco"
X Link @ByMadeleineA 2025-10-19T14:33Z 8079 followers, 5894 engagements